Your Search Results

Devices and strategies in calcified lesions

21 May 2026 – From EuroPCR 2026

Explore advanced devices and techniques for treating calcified coronary lesions in this session. Discussions include the use of Eximer laser coronary atherectomy, novel cutting balloons, outcomes of rotational atherectomy in tortuous vessels, atherectomy combined with drug-coated balloon therapy, and calcium fracture patterns following Shockwave intravascular lithotripsy.

FFR and non-hyperaemic pressure ratios

20 May 2026 – From EuroPCR 2026

This session presents contemporary clinical applications of fractional flow reserve (FFR) and non-hyperaemic pressure ratios (NHPR), highlighting real-world impacts of physiology microcatheter-based indices, the interplay between epicardial stenosis and microvascular resistance, post-PCI hyperemia effects on iFR, and machine-learning driven outcome predictions.

Other right-sided and tricuspid valve interventions

20 May 2026 – From EuroPCR 2026

This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.

Insights from real world TAVI practice

20 May 2026 – From EuroPCR 2026

This session presents comprehensive insights from real-world transcatheter aortic valve implantation (TAVI) practice, including sex differences in coronary assessment, the impact of general anesthesia on aortic valve gradients, early rehospitalisation rates, and the management of TAVI in patients with prior hip arthroplasty. Additionally, it explores multinational...

Frequency and safety of bioprosthetic valve fracture in patients undergoing valve in valve TAVR for failed surgical valves using the SAPIEN 3/Ultra Valves: Insights from real-world data

19 Sep 2022

Michele Pighi provides his take on this trial which aimed to compare the safety and efficacy of VIV-TAVI with or without bioprosthetic valve fracture. It was presented by Santiago Garcia during the TCT Congress 2022.